Biotechnology - Neurological, Gilead Sciences

Filter

Popular Filters

Clinical briefs from Novartis, Gilead and AstraZeneca

13-11-2012

Swiss drug major Novartis (NOVN: VX) has released new two-year results from the largest Phase III study…

ACZ885Anti-Arthritics/RheumaticsAnti-viralsAstraZenecaBiotechnologyCerticanGilead SciencesnaloxegolNeurologicalNovartisPharmaceuticalResearchsofosbuvir

Back to top